Leqembi reaches 10,000 annual prescriptions in China by June 30, 2025? | Binary | | | 6 months ago | |
Total revenue generated by Leqembi in China in 2024 | Categorical | | | 6 months ago | |
Leqembi price reduction announced in China by December 31, 2024? | Binary | | | 6 months ago | |
Leqembi added to China's National Reimbursement Drug List by December 31, 2024? | Binary | | | 6 months ago | |
Will the FDA approve donanemab by August 31, 2024? | Binary | | | 7 months ago | |
What will be the first-year sales figures for donanemab by December 31, 2025? | Categorical | | | 7 months ago | |
How will donanemab compare to Leqembi in market share by December 31, 2024? | Categorical | | | 7 months ago | |
What type of approval will the FDA give to donanemab by August 31, 2024? | Categorical | | | 7 months ago | |
Will Eli Lilly's stock price increase by 5% or more within 7 days of FDA decision on donanemab? | Binary | | | 7 months ago | |
Will the FDA panel recommend approval of donanemab? | Binary | | | 7 months ago | |
Stock market response to FDA approval of injectable Leqembi | Categorical | | | 7 months ago | |
Leqembi injectable available in the US within 3 months of FDA approval? | Binary | | | 7 months ago | |
Reported clinical outcomes of injectable Leqembi in first year post-approval | Categorical | | | 7 months ago | |
Phase 4 studies for injectable Leqembi initiated within 6 months post-approval? | Binary | | | 7 months ago | |
Global expansion of injectable Leqembi post-FDA approval | Categorical | | | 7 months ago | |
FDA approves injectable Leqembi by end of 2024? | Binary | | | 7 months ago | |
Market response to FDA approval of injectable Leqembi | Categorical | | | 7 months ago | |
Injectable Leqembi on U.S. market within 3 months post-approval? | Binary | | | 7 months ago | |
Will the European Commission approve Leqembi for early Alzheimer's by March 31, 2025? | Binary | | | 1 month ago | |
Will Leqembi be approved by the European Medicines Agency (EMA) by July 26, 2025? | Binary | | | 5 months ago | |
Will Eisai and Biogen reapply for Leqembi approval in the EU by December 31, 2024? | Binary | | | 5 months ago | |
Will Eli Lilly's stock reach a $1 trillion market cap by end of 2024? | Binary | | | 6 months ago | |
First hospital to administer Leqembi in China by September 30, 2024 | Categorical | | | 6 months ago | |
FDA approval of injectable Leqembi by end of 2024? | Binary | | | 7 months ago | |
Global approval statuses of injectable Leqembi by end of 2025 | Categorical | | | 7 months ago | |
Clinical benefits of injectable Leqembi in the first year | Categorical | | | 7 months ago | |
Other pharma companies follow Eisai/Biogen by 2025? | Binary | | | 7 months ago | |
What will be the EC's decision on Leqembi by March 31, 2025? | Categorical | | | 1 month ago | |
Will Eli Lilly's Kisunla™ achieve $1 billion in sales in Japan by end of 2024? | Binary | | | 3 months ago | |
Will there be a Leqembi price reduction announcement by August 22, 2025? | Categorical | | | 4 months ago | |
Will NICE revise its decision on Leqembi by June 30, 2025? | Binary | | | 4 months ago | |
Will Leqembi receive approval from another major healthcare system by August 22, 2025? | Binary | | | 4 months ago | |
Will Eisai and Biogen reduce price of Lecanemab in UK by end of 2024? | Binary | | | 4 months ago | |
What will be the total US sales of Leqembi by December 31, 2024? | Categorical | | | 5 months ago | |
Will Biogen's stock price recover to its pre-rejection level by December 31, 2024? | Binary | | | 5 months ago | |
Will Eisai and Biogen announce a new Alzheimer's drug by December 31, 2024? | Binary | | | 5 months ago | |
Will Eli Lilly's stock price increase by 10% or more by end of 2024? | Binary | | | 3 months ago | |
What will be the consensus analyst price target for Eli Lilly stock by end of 2024? | Categorical | | | 6 months ago | |
What will Eli Lilly's stock price be by end of 2024? | Categorical | | | 6 months ago | |
Will Eli Lilly report revenue exceeding $40 billion for fiscal year 2024? | Binary | | | 6 months ago | |
Number of Chinese cities where Leqembi is available by December 31, 2024 | Categorical | | | 6 months ago | |
Which company will dominate the Alzheimer's treatment market in China by end of 2025? | Categorical | | | 5 days ago | |
How many new Alzheimer's treatments will be approved globally by end of 2025? | Categorical | | | 5 days ago | |
Will Donanemab achieve significant market share in China by end of 2025? | Binary | | | 5 days ago | |
Will Eli Lilly's Alzheimer's drug be approved in another major market by end of 2025? | Binary | | | 5 days ago | |
Will a major Alzheimer's treatment breakthrough be published by the US-Korea team by end of 2025? | Binary | | | 5 days ago | |
Which Alzheimer's drug will lead the market share in China by end of 2025? | Categorical | | | 5 days ago | |
Will Biogen's stock rise over 10% within 30 days of EC's Leqembi decision? | Binary | | | 1 month ago | |
What will be Leqembi's market penetration in Europe within a year of approval? | Categorical | | | 1 month ago | |
How will Biogen's stock change one week after EC's Leqembi decision? | Categorical | | | 1 month ago | |
Will Leqembi be approved by another major regulatory body by end of 2025? | Binary | | | 1 month ago | |
Which treatment will have the largest market share for Alzheimer's in Japan by end of 2025? | Categorical | | | 3 months ago | |
Will Kisunla™ receive approval from the European Medicines Agency by June 30, 2025? | Binary | | | 3 months ago | |
How many new Alzheimer's treatments will be approved in Japan by end of 2025? | Categorical | | | 3 months ago | |
What will be Kisunla™'s market share for Alzheimer's treatment in Japan by end of 2025? | Categorical | | | 3 months ago | |
Will Leqembi become available on the NHS by December 31, 2024? | Binary | | | 4 months ago | |
What will be the market uptake of Leqembi in the UK by August 22, 2025? | Categorical | | | 4 months ago | |
Will NHS cover Lecanemab by end of 2024? | Binary | | | 4 months ago | |
Average monthly cost of Lecanemab for private patients in UK by end of 2024? | Categorical | | | 4 months ago | |
Which country will approve Lecanemab for early-stage Alzheimer's next? | Categorical | | | 4 months ago | |
Will UK government provide subsidies for Lecanemab by end of 2024? | Binary | | | 4 months ago | |
How many private prescriptions for Lecanemab in UK by end of 2024? | Categorical | | | 4 months ago | |
How will Biogen's stock price compare to its competitors by December 31, 2024? | Categorical | | | 5 months ago | |
What will be the next major regulatory decision on Leqembi by December 31, 2024? | Categorical | | | 5 months ago | |
Will Leqembi be approved in another major market outside the US and EU by December 31, 2024? | Binary | | | 5 months ago | |
What will Eisai and Biogen's next strategic move be after the CHMP decision by December 31, 2024? | Categorical | | | 5 months ago | |
Where will Eisai and Biogen submit their next major regulatory application for Leqembi by December 31, 2024? | Categorical | | | 5 months ago | |
How will Eisai and Biogen's stock prices change by July 31, 2024, following the CHMP decision? | Categorical | | | 5 months ago | |
What will be Kisunla's market share among Alzheimer's drugs by end of 2024? | Categorical | | | 6 months ago | |
Will Eli Lilly's Alzheimer's drug Kisunla be priced higher than $50,000 per year by end of 2024? | Binary | | | 6 months ago | |
How will public opinion on NHS funding for Leqembi shift by August 22, 2025? | Categorical | | | 4 months ago | |